Back

When Mr. Ahmadi-Khalili first came to our clinic in May 2021, he was suffering from advanced non-small cell lung cancer (NSCLC) with brain metastases. By the end of 2023, the patient had achieved complete remission.

Back
IMG_0164_Portrait

Mr. Ahmadi-Khalili

Lung Cancer

Patients from all over the world choose the Hallwang Clinic in their search for the best lung cancer treatment. One of them is Mr. Ahmadi-Khalili. When he first came to our clinic in May 2021, he was suffering from advanced non-small cell lung cancer (NSCLC) with brain metastases. The previously administered guideline-based immunotherapy with pembrolizumab (Keytruda) in his home country had shown no effect despite high PD-1/L1 expression.

After a comprehensive examination and analysis, our specialized oncology team initiated a targeted combination therapy. The personalized treatment, consisting of a multikinase inhibitor targeting VEGFR, MET, and RET, along with a PD-L1 antibody (atezolizumab) in combination with immune priming, led to significant improvement. After just three months of genetically guided therapy, the treatment was transitioned to immunotherapy alone, administered at intervals of eight to twelve weeks. By the end of 2023, Mr. Ahmadi-Khalili had achieved complete remission. Since then, he has continued immunotherapy at intervals of nine to twelve months as maintenance therapy.

Lung cancer treatment is continuously evolving—particularly through innovative combination therapies that require a high level of expertise and experience in precision medicine. As a leading private oncology clinic with one of the most advanced genomic and immunotherapeutic profiles worldwide, Hallwang Clinic provides first-class, personalized treatment approaches. Thanks to our renowned expert network, close research collaborations, and access to the most innovative therapy options, we set new standards in cancer treatment.

Get in touch with us.
We will gladly assist you!